The decrease in proliferation in HER2−/pHER2Y877+ BC cell lines is observed at a trastuzumab concentration of 50μg/ml, while it appears at 4μg/ml for HER2+ BC cell lines. The gene discussed is ERBB2; the disease is breast cancer.